GHRP-2

Approved (multiple countries)

Growth Hormone Releasing Peptide-2

Category
Growth Hormone
Aliases
Pralmorelin, KP-102
Administration
Subcutaneous injection

Research and regulatory

Development stage

Studied clinically in Japan as a diagnostic agent (pralmorelin) for growth hormone deficiency testing; not FDA approved for any indication in the US.

Legal and regulatory

Approved diagnostic agent in Japan; unscheduled research compound in the US.

Side effects

Increased hunger, mild water retention, potential cortisol/prolactin elevation at higher doses